OBLN - Obalon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 514.08M
Enterprise Value 3-3.73M
Trailing P/E N/A
Forward P/E 1-0.56
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)3.11
Price/Book (mrq)0.70
Enterprise Value/Revenue 3-0.82
Enterprise Value/EBITDA 60.15

Trading Information

Stock Price History

Beta (5Y Monthly) -4.72
52-Week Change 3-89.01%
S&P500 52-Week Change 324.65%
52 Week High 323.2800
52 Week Low 31.5200
50-Day Moving Average 31.8644
200-Day Moving Average 32.4720

Share Statistics

Avg Vol (3 month) 3330.79k
Avg Vol (10 day) 3446.28k
Shares Outstanding 57.69M
Float 5.97M
% Held by Insiders 14.14%
% Held by Institutions 129.94%
Shares Short (Dec. 30, 2019) 41.03M
Short Ratio (Dec. 30, 2019) 43.27
Short % of Float (Dec. 30, 2019) 453.83%
Short % of Shares Outstanding (Dec. 30, 2019) 413.44%
Shares Short (prior month Nov. 28, 2019) 4985.58k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Jul. 24, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2018
Most Recent Quarter (mrq)Sep. 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-569.89%

Management Effectiveness

Return on Assets (ttm)-52.44%
Return on Equity (ttm)-136.85%

Income Statement

Revenue (ttm)4.53M
Revenue Per Share (ttm)1.36
Quarterly Revenue Growth (yoy)-88.90%
Gross Profit (ttm)3.68M
EBITDA -25.3M
Net Income Avi to Common (ttm)-27.52M
Diluted EPS (ttm)-8.2360
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)19.38M
Total Cash Per Share (mrq)2.53
Total Debt (mrq)1.24M
Total Debt/Equity (mrq)6.20
Current Ratio (mrq)5.72
Book Value Per Share (mrq)2.61

Cash Flow Statement

Operating Cash Flow (ttm)-23.4M
Levered Free Cash Flow (ttm)-13.38M